Wendy Pizarro Campbell - 17 Jun 2024 Form 4 Insider Report for Calidi Biotherapeutics, Inc. (CLDI)

Role
Chief Admin. and Legal Officer
Signature
/s/ Andrew Jackson, Attorney-in-fact
Issuer symbol
CLDI
Transactions as of
17 Jun 2024
Net transactions value
$0
Form type
4
Filing time
20 Jun 2024, 20:56:02 UTC
Previous filing
25 Sep 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLDI Stock Options (right to buy) Award +40,000 40,000 17 Jun 2024 Common stock 40,000 $0.1950 Direct F1
transaction CLDI Stock Options (right to buy) Award +60,000 60,000 17 Jun 2024 Common stock 60,000 $0.1950 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to the Issuer's 2023 Equity Incentive Plan (the "2023 Plan"), on June 17, 2024 (the "Grant Date"), the Reporting Person was granted 40,000 incentive stock options at an exercise price of $0.195, which is equal to the closing price of the Issuer's common stock on the Grant Date. The Options shall vest in 1/48th installments on the last day of each monthly period of the Reporting Person's continued service to the Issuer, commencing on 1/1/2024. The options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person.
F2 Pursuant to the Issuer's 2023 Plan, on the Grant Date, the Reporting Person was granted 60,000 Options at an exercise price of $0.195, which is equal to the closing price of the Issuer's common stock on the Grant Date. The Options shall vest in 1/48th installments on the last day of each monthly period of the Reporting Person's continued service to the Issuer, commencing on 5/13/2024. The options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person.

Remarks:

Exhibit 24 - Power of Attorney